Education only · not a recommendation of either topic

Side by side

CJC-1295 vs Sermorelin

Why people compare these. Both are secretagogues in the same family — they prompt the body to release its own growth hormone rather than supplying it directly — so people ask which one “works better.” The honest answer is that neither has evidence for the goals most people bring, and the meaningful differences are about duration of action and regulatory history.

Medically reviewed by Bernard Garcia, MD
What it is
CJC-1295 A synthetic analogue of growth-hormone-releasing hormone (GHRH), modified to remain active in the body for longer than the natural hormone.
Sermorelin A shorter synthetic fragment of GHRH, studied for its effect on the body’s own growth-hormone release.
Research context
CJC-1295 Discussed in early-stage human and animal research on growth-hormone release. Limited to small studies; no large controlled trials for wellness or recovery goals.
Sermorelin Was previously an FDA-approved product for a specific paediatric diagnostic use, later withdrawn from the market for commercial reasons. Research on adult wellness uses is limited.
Research status
CJC-1295 Early human studies · not FDA-approved
Sermorelin Historical approval for a narrow use · limited adult data
Typically discussed for
CJC-1295 Growth-hormone-pathway and recovery conversations
Sermorelin Growth-hormone-pathway conversations

How they differ

Structure and duration. Sermorelin is a short GHRH fragment with a brief action. CJC-1295 is modified to last longer. Longer action is not the same as better, and it changes what a provider would want to monitor.

Regulatory history. Sermorelin was once an FDA-approved product for a narrow diagnostic purpose; CJC-1295 has never been approved for any use. Neither is approved for wellness, recovery, or anti-aging goals.

Evidence for the goals people bring. For recovery, body composition, or sleep, the evidence for both is thin — small studies, surrogate measures, short durations. A provider will weigh that honestly rather than assume one is a safer bet.

Often paired with other topics. Both are frequently discussed alongside secretagogues such as ipamorelin. Combinations multiply the unknowns; they are a conversation for a provider, not a checklist.

Questions for a provider

  • What does the evidence actually show for the goal I have, in people rather than animals?
  • Why would you consider a longer-acting versus a shorter-acting option for someone like me?
  • What would you monitor, and what result would make you stop?
  • Is a growth-hormone-pathway topic even relevant to my situation, or is something else more likely?

Which is right for you?

Neither this page nor any website can answer that. The comparison exists so your conversation with a licensed provider starts from an informed place; the provider decides what, if anything, is appropriate after a confidential intake.

Discuss both with a provider

Free · about 10 minutes · reviewed by a licensed physician

General education · Not medical advice · Provider approval required